fentanyl + dexmedetomidine

Fentanyl + dexmedetomidine is a combination of two pharmaceutical agents used primarily for procedural sedation and analgesia in perioperative and critical care settings. Fentanyl is a potent synthetic opioid agonist at the mu-opioid receptor, providing rapid-onset, short-duration analgesia that is 50 to 100 times more potent than morphine. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that produces sedative, anxiolytic, and modest analgesic effects without significant respiratory depression. When combined, these drugs offer synergistic sedoanalgesic effects—enhancing pain control while reducing the required doses of each agent and minimizing adverse effects such as respiratory depression (from opioids) or hemodynamic instability (from dexmedetomidine). This combination has been studied for use in intravenous patient-controlled analgesia (IV-PCA), procedural sedation during interventional radiology procedures, and as an adjunct to general anesthesia[2][5]. The combination may be associated with improved postoperative pain control compared to either drug alone but requires careful monitoring due to risks of bradycardia, hypotension (dexmedetomidine), or opioid-related side effects[2][5].

Other names

fentanyl and dexmedetomidine